The primary objective of this study is to evaluate the safety and tolerability of intravenous
(IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
The secondary objectives of the study are to:
- Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending
doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
- Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of
single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19
through Week 12.